Endometrial cancer remains the most prevalent gynecologic cancer with continued rising incidence. A less common form of this cancer is uterine serous cancer, which represents 10% of endometrial cancer cases. However, this is the most aggressive cancer. The objective was to assess whether inhibiting the receptor tyrosine kinase AXL with AVB‐500 in combination with bevacizumab would improve response in uterine serous cancer. To prove this, we conducted multiple angiogenesis assays including tube formation assays and angiogenesis invasion assays. In addition, we utilized mouse models with multiple cells lines and subsequently analyzed harvested tissue through immunohistochemistry CD31 staining to assess microvessel density. The combination treatment arms demonstrated decreased angiogenic potential in each assay. In addition, intraperitoneal mouse models demonstrated a significant decrease in tumor burden in two cell lines. The combination of AVB‐500 and bevacizumab reduced tumor burden in vivo and reduced morphogenesis and migration in vitro which are vital to the process of angiogenesis.

Original languageEnglish
Article number5877
Issue number23
StatePublished - Dec 2021


  • AVB‐500
  • AXL inhibition
  • Angiogenesis
  • Bevacizumab
  • Endometrial cancer
  • Recurrent endometrial cancer
  • Uterine serous cancer
  • VEGF inhibition


Dive into the research topics of 'Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer'. Together they form a unique fingerprint.

Cite this